Innate Pharma (IPHA) Non-Current Debt (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Non-Current Debt data on file, last reported at $16.0 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt fell 32.69% year-over-year to $16.0 million; the trailing twelve-month figure through Dec 2025 stood at $16.0 million (down 32.69% YoY), and the FY2025 full-year result was $16.0 million, down 32.69% from the prior year.
• Non-Current Debt for Q4 2025 stood at $16.0 million, down from $20.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $41.0 million in Q4 2022 and bottomed at $13.4 million in Q2 2022.
• The 5-year median for Non-Current Debt is $22.1 million (2024), against an average of $24.8 million.
• The widest annual swing landed in 2021, when Non-Current Debt plunged 99.9%; it then soared 187.85% in 2023.
• A 5-year view of Non-Current Debt shows it stood at $15.4 million in 2021, then surged by 165.18% to $41.0 million in 2022, then slipped by 18.69% to $33.3 million in 2023, then slipped by 28.5% to $23.8 million in 2024, then plunged by 32.69% to $16.0 million in 2025.
• The last three Non-Current Debt figures came in at $16.0 million (Q4 2025), $20.5 million (Q2 2025), and $23.8 million (Q4 2024), per Business Quant data.

Peer Comparison